1. Introduction {#sec1}
===============

In a high-risk remote-living Aboriginal group, we implemented a double-blind randomised controlled trial (RCT) to assess whether angiotensin converting enzyme inhibitor (ACEi) was effective in delaying the onset of albuminuria, hypertension or diabetes among adults "free" of these conditions.

Indigenous people in Australia have a high burden of chronic disease, which is most marked in those who live in the remote regions of the country \[[@bib1], [@bib2], [@bib3], [@bib4]\]. It is characterised by hypertension, kidney disease and type 2 diabetes which affect most of the population by middle age, with high rates of heart attacks, strokes, amputations, blindness, and kidney failure. Rates of hospitalizations for chronic diseases are very high, kidney failure has reached epidemic proportions, and governments are straining to meet the spiralling costs of dialysis treatment \[[@bib5],[@bib6]\].

We conducted two screens, in 1992--1996 and 2004--2006, in the remote Tiwi, Aboriginal community, which both showed high rates albuminuria, hypertension and diabetes in adults and remarkable increases in rates with increasing age \[[@bib7],[@bib8]\]. Among people who were free of the specific markers on the first screen, the estimated incidence between the screens of any or all of the endpoints was between 5.5 and 11 per 100 person years, with the most common marker being new onset albuminuria (unpublished data). We also showed, in a 3.5 year treatment program from late 1995 to November 1999, that treatment of subjects with albuminuria and hypertension with ACEi was associated with significant reductions in blood pressure (BP), and in rates of renal failure and all-cause natural deaths \[[@bib9],[@bib10]\].

The high incidence of new-onset disease we observed, and the demonstrated benefit of treatment on existing disease, led us to question whether treatment with ACEi could prevent or delay subsequent disease onset in people who were, at a given point, disease free. We designed a randomised controlled trial to test this hypothesis.

2. Materials and methods {#sec2}
========================

2.1. Recruitment {#sec2.1}
----------------

Volunteers from the remote community were potentially eligible for participation if they were ≥18 years of age, had no documented history of hypertension, diabetes or renal disease, and had BP ≤ 140/90 mm/Hg, urine albumin creatinine ratio (ACR) \< 3.4 mg/mmol, and no diabetes on their most recent health check, and had no known contraindications to ACEi. A person was defined as diabetic if they had a medical history of diabetes, HbA1c \>6.5% and/or they met the WHO criteria for diabetes on oral glucose challenge \[[@bib11]\].

Reasons for exclusion included: a history of intolerance to ACEi; the presence of other diseases with potential to interfere with or contraindicate treatment; psychosis, or emotional, or intellectual issues that could invalidate informed consent or limit their ability to comply with protocol requirements; and, being a female of childbearing potential who was not using long-term contraception (sterilisation or a contraceptive implant).

Approval for the trial was obtained in 2006 from the community\'s Land Council and the Human Research Ethics Committees (HREC) of the Northern Territory Department of Health and the Menzies School of Health Research (06/34) and The University of Queensland (2006000671). However, the original approval ruled that potentially fertile women be excluded.

Beginning in June 2008, potentially eligible adult community members were identified from community health centre records and from results of the previous 2004--2006 community-wide chronic disease screening program \[[@bib10]\].

Recruitment was delayed due to medicine supply problems, and enrolment, with informed consent, finally began in November 2008. Of 923 identified people contacted for an eligibility interview, 530 (57%) were deemed ineligible due to interim development of established disease or status as a potentially fertile woman. Of the remaining 393, 21 (2%) had died, 85 (9%) refused and 67 (7%) could not be contacted. Thus, only 220 (24%) appeared to be candidates for further eligibility testing. Of these, 160 candidates (33 females and 127 males) were found to be eligible and were subsequently enrolled.

Twenty-eight months into the trial, in February 2011, an ethics amendment was approved to allow enrolment of fertile women who were using long-term contraception. After a slow start, a further 9 women were enrolled between January and February 2012. A total enrolment of 169 adults, 127 (75%) men and 42 women (25%), was achieved.

2.2. Trial procedures {#sec2.2}
---------------------

The intent was to randomise participants to the ACEi perindopril arginine or an inactive, visually identical placebo. Both were supplied by Servier. Participants were provided with 5 mg tablets (or placebo), and prescribed one tablet daily for the first month, then two tablets (10 mg) daily after one month and thereafter, where tolerated. If there was suspicion that the drug was not being tolerated, or if a serious adverse event occurred, treatment was immediately discontinued.

Administration of treatment, and collection of clinical measures and pathology specimens according to the trial\'s protocol, occurred from dedicated offices located near each of the Community\'s health centres.

The intended period of follow-up was 60 months with visits every 2 weeks for the first two months and monthly thereafter. Field staff managed the timing of visits with flexibility, accommodating unplanned events, as well as travel and weather disturbances. They also provided transport of participants to and from the field offices.

At each visit, participants returned their unused tablets, if there were any, at which time a count of tablets was recorded, returned tablets were disposed of and next month\'s allocation was issued. A reasonable degree of treatment adherence was considered to have occurred if participants took, on average, at least 50% of each treatment allocation.

Participants\' data were monitored for departures from the normal range, side effects and adverse events as well as study outcomes. Day to day management was coordinated under the direction of the Chief Investigator. Oversight of the study was provided by an Advisory Committee and all adverse events were reportable to a Data Management Safety Committee. All data collection sheets were sent by airmail and fax to an independent data management unit, the Clinical Informatics and Data Management Unit, Department of Epidemiology and Preventive Medicine, Monash University.

A withdrawal was defined as an early exit that was not an outcome of interest. This occurred either when a participant was excluded by the Chief Investigator on grounds of medical safety or serious breach of trial protocol, or, when a participant withdrew their consent, becoming "lost to follow-up".

2.3. Outcome event variables {#sec2.3}
----------------------------

The composite primary, clinical outcome was defined as hypertension (BP \> 140/90 mm Hg) and/or albuminuria, ACR ≥3.4 mg/mmol, and/or HbA1c \>6.5%, all these components were confirmed by one or two subsequent tests. Secondary outcomes were cardiovascular events, including myocardial infarction, cerebral or coronary ischaemic events and peripheral vascular events, including natural cardiovascular death.

The trial was powered to detect a 50% reduction in the number of primary outcome events with a treatment duration of up to 5 years, a 25% withdrawal rate and at least 114 people in each treatment arm. Calculations drew upon on the findings of the 2004--2006 health screen conducted in the same community in which 55% of adults, or about 600 people meeting the study eligibility criteria, had 5.5--11.2% annual incidence rates of the primary outcome (unpublished data). A minimum sample size requirement for the study was based upon the numbers of people having events in these earlier studies.

2.4. Statistical analysis {#sec2.4}
-------------------------

Analyses were conducted using Stata 14 software \[StataCorp. 2015. *Stata Statistical Software: Release 14*. College Station, TX: StataCorp LP\].

One hundred and twenty-five eligible participants who commenced treatment were included in analyses, utilising a modified intention-to-treat principle. Participants excluded from analyses (44/169) were those who did not commence treatment or those in whom ineligibility became apparent after randomisation.

Mean (SD), geometric mean (95%CI) or proportions were used to summarise variables. Group differences in continuous variables were tested with a *t*-test where variances were equal and distributions approximated normal, or a rank-sum test. A chi^2^ test was used for categorical variables. Skewed continuous variables were assessed using natural and log transformed versions.

Analyses were designed to assess the categorical combined outcome event. Survival time to event analyses were performed to estimate outcome incidence, and Kaplan--Meier survivor functions were tested for equality, using the log-rank test. Despite the intention to report Cox proportional hazard analyses, accounting for baseline age and or sex, it was not possible due to an insufficiency of outcome events. Analyses also examined the distributions of BP, ACR and HbA1c, as continuous variables.

The changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), ACR and HbA1c were modelled with multilevel mixed-effects linear regression. Graphical representations of time-related trends in events were also inspected with locally weighted scatterplot smoothing (Lowess models) to assess the linearity of the relationships of outcome measures to time. All models were assessed with and without adjustment for combinations of the variables sex, baseline age and various degrees of treatment adherence. Those presented restrict follow-up time up to the first 36 months (including exits), so that group numbers were more robust.

3. Results {#sec3}
==========

One hundred and sixty nine adults, 127 (75%) men and 42 women (25%), were randomised. Analyses were conducted on 125 participants (60 ACEi, 65 Placebo), after the exclusion of 44 who either took no treatment (n = 41), principally for reasons related to competitive football, drug and or alcohol use, mental health issues, voluntary or enforced absence from the community and lack of interest, or were falsely enrolled (n = 3), whose ineligibility became apparent after randomisation. The analysis group did not differ significantly by age, sex or randomisation to treatment arm, from those excluded (**A 1**). There was an apparent imbalance in females allocated to the treatment arms (ACEi/placebo), with 10/17 and 10/5 females in the analysis and non-analysis groups respectively (p = 0.065).

Baseline demographic, clinical and biochemical characteristics of the analysis group by treatment arm, are shown in [Table 1](#tbl1){ref-type="table"}. There were no significant differences.Table 1Baseline characteristics, n-125 disease free adults, by treatment arm: Primary Prevention Trial, 2008--2013.Table 1CharacteristicACEi N = 60Placebo N = 65PAge, years; G mean (95% CI)31.7 (29.6--33.9)31.9 (29.7--34.1)0.909Sex; (M/F)50/1048/170.198SBP, mm Hg (mean, SD)114.8 (11.0)113 (10.2)0.475DBP, mm Hg (median, IQR)73.0 (7.6)72.5 (9.1)0.705HbA1c, % (mean, SD)5.7 (0.2) n = 595.7 (0.2) n = 640.955ACR, mg/mmol; G mean (95% CI)0.61 (0.51--0.74)0.76 (0.63--0.92)0.116Weight, kg; G mean (95%CI)61.0 (57.8--64.3) n = 4962.0 (59.0--65.10) n = 550.116Waist circumference, cms; median, IQR80.0 (74.0--91.0) n = 4980.3 (74.3--90.0) n = 520.954Cholesterol, mmol/L; mean, SD5.1 (0.8) n = 604.9 (0.9) n = 630.422HDL, mmol/L; median, IQR1.2 (1.1--1.4) n = 601.2 (1.0--1.4) n = 630.326LDL, mmol/L; mean, SD3.1 (0.8) n = 593.1 (0.8) n = 630.788Triglycerides, mmol/g; G mean (95% CI)1.4 (1.2--1.7) n = 601.2 (1.1--1.4) n = 630.068 0.223 rsum[^1]

The median length of an individual\'s participation was 2.5 years (0.08--4.25 years) in the ACEi arm and 3.0 years (0.08--4.27 years) in the placebo arm, they were not significantly different (p = 0.763). Sixty-five persons (52%) participated up to 3 years, 33 (26%) participated up to 1 year and 11 (8%) participated up to 3 months (not shown). Total person time on treatment was 138.7 person-years in the ACEi arm and 155.4 person-years in the placebo arm, an overall total of 294.1 years. Participation time did not differ by sex (p = 0.600), however, 7% (n = 9) of women were enrolled late in the trial. (Enrollment numbers at specified follow-up time points and a summary of follow-up time, by treatment arm and sex, are shown in **A 2a and b**). Adherence to the tablet regimen was variable, however; 73.3% (44/60) of participants in the ACEi arm took, on average, at least 50% of allocated treatment. There was no difference by sex; 70% of females (7/10) and 73% of males (44/60) had adherence of ≥50% (p = 0.548).

Fifty-nine participants (47%) withdrew from the trial prior to closeout for reasons other than a primary or secondary outcome of interest. Forty-seven participants (38%) were lost to follow-up, which commonly occurred when participants moved to another location, planned a pregnancy or played sport at an elite level. Three people (2.4%), all in the placebo arm, had a serious adverse event. None of these events was found to have a relationship to potential pharmacological toxicity, but they did result from study participation, and led to exclusion from the trial. Nine additional people (7%) were withdrawn due to the onset of medical conditions, all of which were clearly unrelated to study treatment. Six people had serious adverse events that did not necessitate withdrawal. There was no difference in the frequency of any of these categories by treatment arm. **A 3a-b** summarises the withdrawals by treatment arm and further describes the adverse events.

Sixteen primary or secondary outcomes of interest occurred among 15 participants ([Table 2](#tbl2){ref-type="table"}). Six people in the ACEi arm, all males, had 6 events (10% of participants), and the nine people in the placebo arm had 10 events (15.2% of participants). Specifically, 5 people in the ACEi arm developed elevated ACR and one developed myocardial infarction, while in the placebo arm, 4 developed diabetes, 1 hypertension, 3 elevated ACR, 1 myocardial infarction and 1 myocardial ischaemic event, with one of these people (a female) developing both diabetes and elevated ACR. All outcomes in the ACEi arm (all amongst males) were among people with adherence of at least 50% of allocated treatment.Table 2Frequencies of primary and secondary outcome events, by category and treatment arm: Primary Prevention Trial, 2008--2013.Table 2OutcomeACEi\
N = 60Placebo\
N = 65*Primary*Diabetes04Hypertension01Elevated ACR53***Secondary***Cardiovascular event12*Total6 (10%)10 (15.4%)*[^2]

Notably, no females among 10 in the ACEi arm developed any outcomes (0%), while 5 among 17 in the placebo arm (29.4%) did.

There was a trend towards higher numbers of all other outcomes in the Placebo arm, with the exception of elevated ACR. We also examined the outcomes by treatment arm over time (provided in **A 4**); however, no persuasive pattern of difference emerged.

Incidence rates (unadjusted) for the outcome events, per 100 person-years, in females, males and females, and males together, are presented in [Table 3A](#tbl3A){ref-type="table"}, [Table 3B](#tbl3B){ref-type="table"}, [Table 3C](#tbl3C){ref-type="table"}A--C. Notably, the absolute incidence rates in the placebo group, and the 2-fold differences between males and females, are entirely compatible with the (unpublished) data collected in the natural history phase on which the sample size for this trial was originally estimated.Table 3AIncidence rates of outcomes per event by treatment arm: Primary Prevention Trial females, 2008--2013.Table 3AOutcomeACEi\
N = 10 FU: 17.3 pyPlacebo\
N = 18 FU: 45 pyP rates ACEi vs placebo\# events; rate (CI) per 100 py\# events; rate (CI) per 100 pyDiabetes0; 03; 6.7 (2.2--20.7)0.382Hypertension0; 00; 0NAElevated ACR0; 01; 2.2 (0.3--15.8)0.547Cardiovascular0; 01; 2.2 (0.3--15.8)0.706Non-ACR0; 04; 8.9 (3.3--23.7)0.342*Any/all0; 05; 11.1 (4.6 -- 26.7)0.251*Table 3BIncidence rates of outcomes per event by treatment arm: Primary Prevention Trial males, 2008--2013.Table 3BOutcomeACEi\
N = 50 FU: 121.4 pyPlacebo\
N = 48 FU: 112.7 pyP rates ACEi vs placebo\# events; rate (CI) per 100 py\# events; rates (CI) per 100 pyDiabetes0; 01; 0.9 (0.1--6.3)0.289Hypertension0; 01; 0.9 (0.1--6.3)0.239Elevated ACR5; 4.1 (1.7--9.9)2; 1.8 (0.5--7.1)0.283Cardiovascular1; 0.8 (0.1--5.9)1; 0.9 (0.1--6.3)\
0.950Non-ACR1; 0.8 (0.1--5.9)3; 2.7 (0.9--8.3)0.246*Any/all6; 4.9 (2.2 -- 11.0)5; 4.4 (1.9-- 10.7)0.873*Table 3CIncidence rates of outcomes per event by treatment arm: Primary Prevention Trial females and males, 2008--2013.Table 3COutcomeACEi\
N = 60 FU: 138.7 pyPlacebo\
N = 66 FU: 157.7 pyP rates ACEi vs placebo\# events; rate (CI) per 100 py\# events; rate (CI) per 100 pyDiabetes0; 04; 2.5 (1.0--6.8)0.072Hypertension0; 01; 0.6 (0.09--4.5)0.330Elevated ACR5; 3.6 (1.5--8.7)3; 1.9 (0.6--5.9)0.357Cardiovascular1; 0.7 (0.1--5.1)2; 1.3 (0.3--5.1)0.670Non-ACR1; 0.7 (0.1--5.1)7; 4.4 (2.1--9.3)0.060*Any/all6; 4.3 (1.9 -- 9.6)10; 6.3 (3.4 -11.8)*0.500[^3]

The tables show that diabetes, hypertension and secondary outcome events were more common in the placebo arm in both females and males (**3A,B**). In combination, these "non-ACR" events occurred at a rate of 0.7 (0.1--5.1) per 100 person-years in the ACEi arm, and at a rate of 4.4 (2.1--9.3) per 100 person-years in the placebo arm (**3C**). The difference in these rates approached significance (P = 0.060). There was also a higher, although non-significant (p = 0.500), rate of a combined event of all primary and secondary outcomes in the placebo arm among all participants (**3C**). None of the ten females in the ACEi arm experienced any event (0%), in contrast to 5 out of 17 females (28%) in the placebo arm, at a rate of 11.1 (4.6--26.7) per 100 person-years: however, the difference was not significant (P = 0.251) (**3A**).

Kaplan-Meier survival curves of the outcome events combined, by treatment arm, in females, males, and females and males together ([Fig. 1](#fig1){ref-type="fig"}A--C), highlight the wider discrepancy in the female rather than the male rates.Fig. 1A--C. Kaplan-Meier survival curves of all events by treatment arm and sex: Primary Prevention Trial, 2008-2013Note: ACEi, angiotensin converting enzyme inhibitor; P, log-rank tests of equality calculated from Kaplan-Meier survival functions (unadjusted).Fig. 1

Cox proportional hazards models for a combined outcome event in all participants suggested a lower rate of events in the ACEi arm, although non-significant (not shown). It was not possible to derive estimates for females separately as there were no events among females in the ACEi arm.

Changes over time (up to 36 months of follow-up) in the outcome measures of HbA1c, ACR, SBP and DBP, without additional adjustment or exclusion of outlying values, are summarised in **A 5**. In females there was no significant difference between the ACEi and placebo arms for any of these outcomes, however, they all, particularly ACR, had a non-significant tendency to be at a lower level in the ACEi arm.

Males in the treatment arm showed no benefit for HbA1c, and a non-significant trend towards benefit in SBP.

Adjustment for age at randomisation did not alter any findings.

Lowess modelling, without adjustment (see [Fig. 2](#fig2){ref-type="fig"}A--H), lends support to these findings and indicates that the relationships may not be linear.Fig. 2A--H., HbA1c, ACR, SBP and DBP levels over time, by sex, and treatment group: Primary Prevention Trial, 2008-2013Note: Graphs show locally weighted scatterplot smoothing of unadjusted estimates for the period of up to the 36 month of follow-up; HbA1c, glycosylated haemoglobin A 1c; ACR, albumin creatinine ratio; SBP, systolic blood pressure (mm/Hg); DBP, diastolic blood pressure (mm/Hg).Fig. 2

4. Discussion {#sec4}
=============

This was the first randomised controlled trial of pharmaceutical prevention of albuminuria, hypertension or diabetes in the setting of a high-risk remote-living Australian Aboriginal group. It was conducted in a very challenging environment with multiple logistic hurdles.

Delayed ethics approval for commencement of the trial led to a prolonged recruitment period in which the pool of potentially eligible participants was reduced by new incidence of interim disease, reflecting the high rates of disease experienced by the community. Additionally, numbers of enrolled females were lower than anticipated, due to delay of approval for the enrolment of fertile women who were using long-term contraception, until the final two years of the trial. In remote settings Aboriginal women, compared to men, have higher levels of elevated ACR and higher incidence of new onset ACR up through early adult life \[[@bib12]\] and females also have significantly higher levels of end stage kidney disease leading to RRT \[[@bib13],[@bib14]\]. Exclusion of potentially fertile women at the outset of the trial (and the inference that they were not capable of managing their own fertility) created a negativity towards the trial in both sexes, and contributed to the high withdrawal rate of 47%, which was higher than the estimate of 25% used in power calculations. The recruitment goal of ≥114 people in each arm was not achieved. Based upon the minimum requirement, and among those analysed, there was a 14% deficit in male and a 76% deficit in female enrolment.

Analyses were stymied by their lack of power, related to the small unbalanced numbers of participants and outcomes, as well as to recruitment biases and considerable periods of poor quality adherence data. Field Staff reported instances of periodic medicine supply failure due to weather events and tablet production problems, potential participant awareness of their randomisation due to cosmetic differences in tablets, and questionable accuracy of returned tablet count registrations.

Elevated ACR was the most frequent outcome, but it was not significantly more frequent in the placebo than the treatment arm. A possible treatment benefit in terms of a combined diabetes, hypertension outcome, and, arguably, on cardiovascular events, however, does lend support to our hypothesis, as do the observed tendencies for lower SBP and HbA1c in the ACEi arm during follow-up. In 2001 the HOPE study reported that new onset of diabetes, using elevated HbA1c as the diagnostic marker, was reduced in individuals taking the ACEi, Ramipril, compared to those on Placebo \[[@bib15]\].

5. Conclusion {#sec5}
=============

We present a catalogue of events describing an RCT of ACEi in a remote Aboriginal Australian community. There was sub-optimal recruitment, a gender imbalance, a small sample size, and subsequent difficulty in interpreting the data. Nonetheless, there was a suggestion of benefit of ACEi in females for all endpoints, and a trend towards benefit on non-ACR endpoints when both sexes were examined together. In view of the huge burden of chronic disease in these communities, consideration should be given to repeating some aspects of such a trial under better conditions.

Trial registration {#sec6}
==================

Australian New Zealand Clinical Trials Registration, Number 12608000371392.
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[^1]: Note: P = *t*-test, ranksum or chi^2^, SD = standard deviation, IQR = inter-quartile range, ACR = albumin creatinine ratio, SBP = systolic blood pressure, DBP = diastolic blood pressure, G mean = geometric mean.

[^2]: Note: Elevated ACR = albumin creatinine ratio ≥3.4 mg/mmol; represents 16 events among 15 people, a combined elevated ACR and diabetes outcome occurred in one person in the placebo arm.

[^3]: Note: ACEi, angiotensin converting enzyme inhibitor; P, log-rank tests of equality calculated from Kaplan-Meier survival functions (unadjusted); FU, follow-up period; py, person-years; CI, 95% confidence interval; \#, number; ACR, albumin creatinine ratio mg/mmol.
